Cure My Disease

Don't miss your cure!

 Log in / Sign up

Wearable sensors aim to catch neurodegenerative decline in real time

NCT ID NCT04753320

Knowledge-focused Sponsor: Massachusetts General Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 23, 2026 · Last updated Jul 30, 2026 · Updated 3 times

Summary

This observational study tests whether wearable sensors and digital health tools can reliably measure falls, movement, speech, and thinking skills in people with progressive supranuclear palsy, Parkinson's disease, or multiple system atrophy. Participants wear a pendant sensor and complete monthly remote assessments plus in-person visits every six months for about a year. The goal is to see if this approach is practical and accurate enough for home monitoring.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this approach could enable more frequent, real-world tracking of disease progression in neurodegenerative conditions, potentially improving clinical trial efficiency and patient care.
What could go wrong
This is an early feasibility study with only 85 participants. The technology may not be accurate enough or acceptable to patients over the long term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 85 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

All participants with clinical diagnosis of possible or probable PSP, probable PD, or possible or probable MSA are eligible to participate in this study. Participants must be able to ambulate unassisted for 10 feet in order to perform gait and balance tests.

Ages

18 to 89 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Clinical diagnosis of possible or probable PSP phenotype as defined by the 2017 MDS criteria, clinical diagnosis of at least probable PD as defined by the 2015 MDS criteria, or clinical diagnosis of at least probable MSA as defined by the 2022 MDS criteria, or healthy controls. * Male or female, aged 18 to 89 years, inclusive. * Fluent in reading and speaking English. * Capable of providing informed consent based on the investigator's judgment. * Able to comply with the protocol based on the investigator's judgment. * Able to walk 10 feet unassisted. * With access to a caregiver who is able to assist with all study-related procedures. Exclusion Criteria: * Any neurological, medical, or psychiatric condition that would preclude participation in study activities based on the investigator's judgment. * A history of frequent falls defined as more than 5 falls/month or requirement of a walker to ambulate safely.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Msa - multiple system atrophy are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

multiple system atrophy Parkinson disease progressive supranuclear palsy Shy-Drager Syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Msa - multiple system atrophy Parkinson disease Progressive supranuclear palsy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Johns Hopkins

    Baltimore, Maryland, 21093, United States

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.